Phathom Pharmaceuticals (PHAT) Cost of Revenue (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Cost of Revenue data on file, last reported at $12.0 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $12.0 million, up 222.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.9 million (up 173.91% YoY), and the FY2025 annual result was $22.6 million, up 183.44% from the prior year.
• Cost of Revenue advanced to $12.0 million in Q1 2026 per PHAT's latest filing, from $7.6 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $12.0 million in Q1 2026 and troughed at $167000.0 in Q4 2023.
• A 4-year average of $4.3 million and a median of $3.8 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue jumped 2184.43% in 2024, then jumped 100.47% in 2025.
• A 4-year view of Cost of Revenue shows it stood at $167000.0 in 2023, then jumped by 2184.43% to $3.8 million in 2024, then soared by 100.47% to $7.6 million in 2025, then soared by 56.85% to $12.0 million in 2026.
• Business Quant data shows PHAT's Cost of Revenue at $12.0 million in Q1 2026, $7.6 million in Q4 2025, and $6.2 million in Q3 2025.